☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Axsome
Axsome Reports (SHARP) Study Results of Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Obstructive Sleep A...
October 3, 2022
Axsome’s Auvelity Receives the US FDA’s Approval for the Treatment of Major Depressive Disorder
August 19, 2022
Axsome Publishes Results of AXS-05 (dextromethorphan-bupropion) in P-III (GEMINI) Trial for Major Depressive Disorder in The Journ...
June 2, 2022
Axsome Entered into a Definitive Agreement to Acquire Sunosi from Jazz for the Treatment of Excessive Daytime Sleepiness
March 28, 2022
Insights+: Breakthrough Therapy Designation by the US FDA in 2020
March 11, 2021
PharmaShots Weekly Snapshot (January 13-17, 2020)
January 20, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.